Aethlon Medical (NASDAQ:AEMD – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Insider and Institutional Ownership
2.0% of Aethlon Medical shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 1.1% of Aethlon Medical shares are owned by company insiders. Comparatively, 22.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Aethlon Medical and NeuroPace”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aethlon Medical | $570,000.00 | 15.08 | -$12.21 million | ($2.82) | -0.22 |
| NeuroPace | $65.42 million | 5.62 | -$32.96 million | ($1.00) | -12.31 |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Aethlon Medical and NeuroPace, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aethlon Medical | 0 | 0 | 1 | 0 | 3.00 |
| NeuroPace | 0 | 1 | 4 | 0 | 2.80 |
Aethlon Medical presently has a consensus target price of $7.00, indicating a potential upside of 1,037.10%. NeuroPace has a consensus target price of $14.80, indicating a potential upside of 20.23%. Given Aethlon Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe Aethlon Medical is more favorable than NeuroPace.
Profitability
This table compares Aethlon Medical and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aethlon Medical | N/A | -160.36% | -115.74% |
| NeuroPace | -36.74% | -205.41% | -28.29% |
Risk and Volatility
Aethlon Medical has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.
About Aethlon Medical
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
